Aficamten (CK-3773274)

Why It Matters

The approval adds a more easily titrated myosin inhibitor to the limited oHCM therapeutic arsenal and may capture market share from existing drugs. Success in non‑obstructive HCM could position aficamten as the first dual‑indication myosin inhibitor, reshaping treatment standards.

Key Takeaways

• FDA approved oral myosin inhibitor for obstructive HCM
• Reversible allosteric design simplifies dose titration
• Phase 3 trial showed significant cardiac function improvement
• Outperformed metoprolol in exercise capacity and symptoms
• Ongoing studies target non‑obstructive HCM indication

Pulse Analysis

Hypertrophic cardiomyopathy remains a leading cause of unexplained left‑ventricular hypertrophy, affecting roughly 1 in 500 adults worldwide. Traditional management relies on beta‑blockers, calcium‑channel blockers, or invasive septal reduction, leaving a therapeutic gap for disease‑modifying agents. Cardiac myosin inhibitors emerged to address this gap by directly modulating the hypercontractile sarcomere, offering a mechanistic approach that can reduce outflow tract gradients and improve quality of life.

Aficamten distinguishes itself through a reversible, allosteric binding profile that permits rapid dose adjustments, a notable advantage over mavacamten’s longer half‑life and more complex titration algorithm. In the pivotal Phase 3 trial, patients receiving aficamten experienced statistically significant reductions in left‑ventricular outflow tract gradients and marked improvements in NYHA functional class. A head‑to‑head comparison with metoprolol demonstrated superior gains in peak VO₂ and symptom scores, underscoring the drug’s potential to become a first‑line oral therapy for oHCM. The simplified titration also reduces the monitoring burden on clinicians, facilitating broader adoption in community cardiology practices.

The strategic importance of aficamten extends beyond its current indication. Ongoing studies targeting non‑obstructive HCM could make it the first myosin inhibitor with dual‑indication labeling, a differentiation that may capture market share from both mavacamten and conventional pharmacotherapy. If successful, the expanded label would address a sizable unmet patient population, driving revenue growth for Cytokinetics and influencing payer formularies. Moreover, the drug’s safety profile and oral administration align with the industry’s shift toward patient‑centric, outpatient‑focused treatments, positioning aficamten as a pivotal player in the evolving cardiology therapeutic landscape.